Eric Daar, IDWeek 2021: Metabolic Complications among Treatment-naïve Adults Living with HIV-1
It was a pleasure to meet with Prof. Eric Daar (Harbor-UCLA Medical Center, West Carson, CA, USA) to discuss his study investigating metabolic complications among treatment-naïve adults living with HIV-1. Part 1 of this interview can be found here.
The abstract entitled: ‘Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.
- What were the aims and methodology of your study investigating metabolic complications among treatment-naïve adults living with HIV-1? (0:18)
- What were the findings for each treatment regimen studied? (2:11)
- What were the strengths and limitations of this study? (5:16)
- What questions remain unanswered and what future studies are planned? (6:54)
Disclosures: Eric Daar is a consultant for Gilead and Merck, and receives research support from Gilead, Merck and ViiV Healthcare.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of IDWeek, Virtual 2021
Share this Video
Related Videos In HIV
Jeffrey Kwong, ACTHIV 2023: Sexual health in older adults living with HIV, clinical considerations for PrEP, and HIV prevention promotion
Sexual health in the aging process is crucial for healthcare professionals to be educated on due to its significant impact on overall well-being and quality of life for older adults living with HIV. In this interview, we speak with Prof. Jeffrey Kwong (Rutgers School of Nursing, Newark, NJ, USA) to explore the importance of addressing […]
Amphotericin B, an oral lipid nanocrystal for cryptococcal meningitis, phase 2 results: David Boulware, ECCMID 2023
Intravenous amphotericin B is a mainstay of treatment in cryptococcal meningitis, in this phase 2 study the efficacy and safety of amphotericin B, a novel, orally absorbed, less-toxic formulation is investigated. It was a pleasure to talk with Prof. David Boulware (University of Minnesota, Minneapolis, USA) to learn more around the prevalence, clinical presentations and […]
Bifast study: efficacy and safety of immediate start of BIC/FTC/TAF after HIV diagnosis: Aws Waleed M. Al-Hayani, ECCMID 2023
After HIV diagnosis, antiretroviral therapy is indicated to be started as early as possible, the phase 4 Bifast study looked at the efficacy and safety of BIC/FTC/TAF when initiated at the first HIV-specialist appointment. In this interview with Dr. Aws Waleed M. Al-Hayani (Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain) we discuss the controversies surrounding […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!